Bank of America sets USD 140.00 target for Incyte stock

Published on 10/17/2026 at 18:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Incyte's market value was USD 22.9 billion on October 16, 2026. Incyte stock last traded at USD 113.07 on October 16, 2026, down 0.18 percent on Nasdaq.

Analyst targets and market measures

On October 16, 2026, Bank of America Securities set a USD 140.00 target for Incyte.
Incyte's market capitalization was USD 22.9 billion on October 16, 2026.
Incyte stock last traded at USD 113.07 on October 16, 2026 at 4:00 p.m. ET, down 0.18 percent on Nasdaq.
UBS raised its target from USD 113.00 to USD 127.00 on October 5, 2026.

Extreme Makrofotografie einer Pharmakapsel mit blauem und weißem Granulat — Incyte Wirkstoffkapsel in extremer Makroaufnahme zeigt Granulat, steht für Innovation ISIN US45337C1027, Illustration mit AI erstellt.

Incyte (ISIN US45337C1027) received a USD 140.00 price target from Bank of America Securities analyst Tazeen Ahmad on October 16, 2026. According to The Globe and Mail, the analyst reiterated a Buy rating alongside the target. The last Nasdaq quote was USD 113.07 on October 16, 2026 at 4:00 p.m. ET, down 0.18 percent from USD 113.27.

Target distance reaches 23.82 percent

The Bank of America target stands 23.82 percent above the October 16 Nasdaq price. That gap gives the analyst view a measurable market context, while the rating itself remains a third-party assessment rather than a company forecast.

Second-quarter revenue rose 37.70 percent

For the second quarter ended June 30, 2026, Incyte reported revenue of USD 1.67 billion, up 37.70 percent from the year-earlier period. Net income reached USD 585.61 million. The figures were reported by The Globe and Mail.

Yearly range and trading volume

Incyte traded between USD 112.01 and USD 114.57 during the October 16 session. The USD 113.07 price stood 14.74 percent below the 52-week high of USD 132.60 and 34.57 percent above the low of USD 84.02. Volume was 1,580,116 shares, 3.91 percent below the average of 1,644,467 shares.

Valuation has two visible markers

Incyte's market capitalization was USD 22.9 billion and its price-to-earnings ratio was 14.40 on October 16, 2026. UBS had raised its target from USD 113.00 to USD 127.00 on October 5, 2026, according to Investing.com. That target was 12.32 percent above the October 16 price.

Comparison with peers

The October 16 market data place Incyte alongside larger pharmaceutical companies as follows:

Incyte (Nasdaq, USD): minus 0.18 percent, P/E 14.40, market capitalization USD 22.9 billion.

Bristol-Myers Squibb (NYSE, USD): minus 1.35 percent, P/E 13.16, market capitalization USD 122.1 billion.

Gilead Sciences (Nasdaq, USD): minus 0.75 percent, P/E minus 58.50, market capitalization USD 193.7 billion.

Nasdaq quote stays below yearly high

Incyte's October 16 Nasdaq quote was 14.74 percent below its 52-week high, while the company continues to present itself as a global biopharmaceutical business across hematology, oncology, inflammation and autoimmunity, according to Incyte.